ESTRO 2022 - Abstract Book

S455

Abstract book

ESTRO 2022

Conclusion This prospective CED registration program demonstrates that it is feasible to monitor practice patterns and outcome of innovative radiotherapy techniques, such as SBRT, in the real-life setting. Although patient, disease and treatment characteristics varied, survival data conformed to those reported in the literature. On this basis, SBRT has been formally included in the Belgian reimbursement system as of January 2020.

OC-0506 Salivary gland dose response modelling using PSMA PET/CT

V. Mohan 1 , N. Bruin 2 , J. van de Kamer 1 , J. Sonke 1 , W. Vogel 2

1 Netherlands Cancer Institute, Radiation Oncology, Amsterdam, The Netherlands; 2 Netherlands Cancer Institute, Radiation Oncology and Nuclear Medicine, Amsterdam, The Netherlands Purpose or Objective Xerostomia remains a common side effect of radiotherapy (RT) for patients with head and neck (H&N) cancer despite advancements in treatment planning and delivery. Molecular PET imaging of the prostate specific membrane antigen (using 68 Ga/ 18 F-PSMA) is highly specific to prostate cancer, but uptake in salivary glands reflects the presence of generally abundantly PSMA-positive secretory cells. We aimed to objectively quantify the dose-response of salivary glands using PSMA PET.

Materials and Methods